Quantcast

ViGeneron closes Series A round which attracts WuXi AppTec and Sequoia Capital China

ViGeneron GmbH, a gene therapy company, announced the closing of its series A financing round led by WuXi AppTec and Sequoia Capital China, which will enable ViGeneron to accelerate its proprietary viral vector-based gene therapy platforms and drive product development in its two lead ophthalmic gene therapy programs.

Read more

Entyvio shows superiority over Humira in first head-to-head biologic study in ulcerative colitis

Takeda announced further results from the Varsity study, which demonstrated the superiority of the gut-selective biologic vedolizumab (Entyvio) to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira) in achieving the primary endpoint of clinical remission at week 52 in patients with moderately to severely active ulcerative colitis

Read more

Newron Pharmaceuticals: Commercialization partner Meiji Seika together with Eisai get approval of Safinamide for Parkinson’s Disease in Japan

Italian biopharmaceutical specialist for nervous diseases solutions, Newron Pharmaceuticals, and it’s partners Meiji Seika Pharma together with Eisai, got approval to produce and sell Equifina tablets in Japan.

Read more